Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Tourette Syndrome

National Center for Research Resources (NCRR)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Tourette Syndrome cohort.

Asset / SponsorPhaseRating
Guanfacine
National Center for Research Resources (NCRR)
Phase 3BB
Risperdal
National Center for Research Resources (NCRR)
Phase 2B
Pimozide
National Center for Research Resources (NCRR)
Phase 2B
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 2CCC
Marijuana
OMNI Medical Services, LLC
Phase 2CCC
Pergolide
Children's Hospital Medical Center, Cincinnati
N/AD

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →